BACKGROUND AND OBJECTIVES: Early decline in GFR may reflect progressive kidney disease in type 1 diabetes, but its predictive value in type 2 diabetes is uncertain. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this longitudinal study, GFR was measured serially over approximately 4.0 years in 195 Pima Indians with type 2 diabetes. Renal function decline (RFD) was defined during this initial period by an average GFR loss ≥3.3%/yr, as defined previously in type 1 diabetes. Subsequently, participants were followed for up to 17.8 years to ESRD onset, death, or December 31, 2010, whichever came first. RESULTS: RFD prevalence during the initial period was 32% in 68 participants with normal baseline albuminuria (albumin/creatinine ratio [ACR] < 30 mg/g), 42% in 88 with microalbuminuria (ACR 30 to <300 mg/g), and 74% in 39 with macroalbuminuria (ACR ≥300 mg/g; P<0.001). The cumulative incidence of ESRD 10 years after the initial period was 41% in those with RFD and 15% in those without (P<0.001); 41 of the 49 ESRD cases (83.7%) occurred in participants who had or developed macroalbuminuria during the initial period. When adjusted for age, sex, diabetes duration, and hemoglobin A1c, the ESRD hazard rate was 4.78 times (95% confidence interval, 2.39-9.58) as high in those with RFD as in those without; further adjustment for albuminuria attenuated this association (hazard ratio, 1.79; 95% confidence interval, 0.82-3.91). CONCLUSIONS: In type 2 diabetes, loss of GFR often occurs before the onset of macroalbuminuria, but a decline predictive of ESRD is strongly dependent on progression to macroalbuminuria.
BACKGROUND AND OBJECTIVES: Early decline in GFR may reflect progressive kidney disease in type 1 diabetes, but its predictive value in type 2 diabetes is uncertain. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this longitudinal study, GFR was measured serially over approximately 4.0 years in 195 Pima Indians with type 2 diabetes. Renal function decline (RFD) was defined during this initial period by an average GFR loss ≥3.3%/yr, as defined previously in type 1 diabetes. Subsequently, participants were followed for up to 17.8 years to ESRD onset, death, or December 31, 2010, whichever came first. RESULTS: RFD prevalence during the initial period was 32% in 68 participants with normal baseline albuminuria (albumin/creatinine ratio [ACR] < 30 mg/g), 42% in 88 with microalbuminuria (ACR 30 to <300 mg/g), and 74% in 39 with macroalbuminuria (ACR ≥300 mg/g; P<0.001). The cumulative incidence of ESRD 10 years after the initial period was 41% in those with RFD and 15% in those without (P<0.001); 41 of the 49 ESRD cases (83.7%) occurred in participants who had or developed macroalbuminuria during the initial period. When adjusted for age, sex, diabetes duration, and hemoglobin A1c, the ESRD hazard rate was 4.78 times (95% confidence interval, 2.39-9.58) as high in those with RFD as in those without; further adjustment for albuminuria attenuated this association (hazard ratio, 1.79; 95% confidence interval, 0.82-3.91). CONCLUSIONS: In type 2 diabetes, loss of GFR often occurs before the onset of macroalbuminuria, but a decline predictive of ESRD is strongly dependent on progression to macroalbuminuria.
Authors: Kevin V Lemley; Derek B Boothroyd; Kristina L Blouch; Robert G Nelson; Lois I Jones; Richard A Olshen; Bryan D Myers Journal: Am J Physiol Renal Physiol Date: 2005-05-17
Authors: Bruce A Perkins; Robert G Nelson; Betsy E P Ostrander; Kristina L Blouch; Andrzej S Krolewski; Bryan D Myers; James H Warram Journal: J Am Soc Nephrol Date: 2005-03-23 Impact factor: 10.121
Authors: R G Nelson; M Tan; G J Beck; P H Bennett; W C Knowler; W E Mitch; K Blouch; B D Myers Journal: Diabetologia Date: 1999-01 Impact factor: 10.122
Authors: R L Chaiken; M Eckert-Norton; M Bard; M A Banerji; J Palmisano; I Sachimechi; H E Lebovitz Journal: Diabetes Care Date: 1998-12 Impact factor: 19.112
Authors: Bruce A Perkins; Linda H Ficociello; Kristen H Silva; Dianne M Finkelstein; James H Warram; Andrzej S Krolewski Journal: N Engl J Med Date: 2003-06-05 Impact factor: 91.245
Authors: B D Myers; R G Nelson; G W Williams; P H Bennett; S A Hardy; R L Berg; N Loon; W C Knowler; W E Mitch Journal: J Clin Invest Date: 1991-08 Impact factor: 14.808
Authors: Meda E Pavkov; William C Knowler; Robert L Hanson; Desmond E Williams; Kevin V Lemley; Bryan D Myers; Robert G Nelson Journal: Am J Kidney Dis Date: 2013-01-21 Impact factor: 8.860
Authors: Gudeta D Fufaa; E Jennifer Weil; Kevin V Lemley; William C Knowler; Frank C Brosius; Berne Yee; Michael Mauer; Robert G Nelson Journal: Clin J Am Soc Nephrol Date: 2016-01-20 Impact factor: 8.237